Takeda Pharmaceutical Co. has entered an agreement to acquire LigoCyte Pharmaceuticals, a privately held biopharma company specializing in vaccine products, for an upfront payment of $60 million plus milestone payments based on the progress of development projects. LigoCyte’s lead product, a vaccine to prevent norovirus gastroenteritis, is currently in Phase I/II development.   “Takeda’s acquisition of LigoCyte is a major step forward in the expansion of Takeda’s vaccine business, and a demonstr...